alt Hacker News150% increase is because it started from a low point. Moderna's stock lost 94% value after Covid. Stock price speaks to investors' enthusiasm, there is no algorithm.
> This phase 3 news so far is nothing more than a press release.
Can you find a case where a press release after phase 3 was later proven wrong? They do have the data, and most likely the data is positive. They're talking about FDA's approval as soon as late 2027, which is fairly soon.
Do you know what would be more dramatic than stock gaining 150%? that'd be the stock crashing if the press release turned out to be wrong. Follow the money if you are skeptical. See who's selling.
> The flashy 49% figures are from the old 157 only patient Phase 2, not this Phase 3 trial.
There are 1,100 patients in phase 3. More evidence that they're pretty confident.
This is great news.
>> Can you find a case where a press release after phase 3 was later proven wrong?
Galera Therapeutics, Actimmune, leronlimab, roxadustat, tivozanib, aducanumab, tebipenem are all examples of Phase 3 massive failures.
>> This is great news.
Looking forward to the stock market reacting with the same level of due diligence show here, when the actual science data is published...in a still not announced distant future... :-)